---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-114996"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T15:46:37.336897+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rhythm Pharma Q3 IMCIVREE revenue $22.5M, net loss $44.2M; Phase 3 hypothalamic obesity on track

## Summary
- Q3 2023 net product revenue from IMCIVREE $22.5M vs $4.3M in Q3 2022; 80% from U.S.
- Net loss of $44.2M ($0.76 per share) vs $40.9M loss ($0.79 per share) in Q3 2022.
- Phase 3 hypothalamic obesity trial expects full enrollment by end of 2023; 25.5% mean BMI reduction at 1 year in long-term extension (n=12).
- Cash & investments $299.3M as of Sep 30, 2023, sufficient to fund operations into 2026.
- Company expects 2023 Non-GAAP operating expenses $210M-$220M (R&D $125M-$130M, SG&A $85M-$90M).

## SEC filing metadata
- accession: 0001104659-23-114996
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000110465923114996/0001104659-23-114996-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000110465923114996/tm2329850d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-114996
- JSON: https://secwatch.observer/filing/0001104659-23-114996.json
- Plain text: https://secwatch.observer/filing/0001104659-23-114996.txt

## Key facts
- Earnings Releases
  RHYTHM PHARMACEUTICALS, INC. reported the third quarter ended September 30, 2023 results: revenue $22.5 million.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $22.5 million
  - Result: reported results
  source text: Third quarter 2023 net revenue from global sales of IMCIVREE ® (setmelanotide) of $22.5 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649904/000110465923114996/0001104659-23-114996-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.